The bottom line: We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades.

This global company is way oversold analysts say. The post How high does UBS think CSL shares will go? appeared first on The ...

A global biopharmaceutical company has announced it will invest $1. 5 billion for a new manufacturing facility in Bradley, ...

The most recent earnings report from CSL Limited (ASX:CSL) was disappointing for shareholders. Despite the soft profit numbers, our analysis has optimistic about the overall quality of the income ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move ...

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. Markets fared ...

Here's what to expect from the Biotech stock next. The post 3 reasons why the CSL share price could leap 87% to $274! appeared first on The Motley Fool Australia.

A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...

The company has long been one of the highest-quality businesses on the ASX, which makes its recent decline even more surprising. The post What on earth's going on with the CSL share price? appeared ...

Pro Medicus and Telix Pharmaceuticals are likely to be ejected from key S&P/ASX indices at the next reweighting, but 4D ...

Sharesight is a portfolio tracker that is integrated into Morningstar Investor. Their data shows the top 20 trades by ...